InvestorsHub Logo
icon url

terry hallinan

02/28/04 2:12 PM

#12752 RE: SlopsterSlasher #12741

SlopsterSlasher,

Thank you very much for pasting that.

Whatever the status of DNAP's business prospects in the immediate future, the quoted material inherently contains a most optimistic assessment of scientific value of DNAP's technology despite numerous internal contradictions:

>> Therefore, our results suggest that the mis-reporting of majority race is not a very significant event, and that authors such as Risch and Rosenberg are correct to attach value to self-reported racial classifications, and that determination of majority ancestry affiliation is not the main problem with current self-reporting methods. The problem is that even if a patient knows their majority affiliation, classifying a patient in a single group sacrifices more subtle information related to population structure and sub-structure. Not only is this exercise inaccurate and misleading if the patient is of admixed ancestry, and many patients are, but it is also equally problematic for those who not even know that they are of admixed ancestry. We also observed considerable admixture within a significant percentage of individuals we have tested to date, and considerable structure within most majority BGA groups as well, and it is not unreasonable to suspect that this admixture may have some bearing on drug response.<<

Best, Terry